79 related articles for article (PubMed ID: 3039199)
1. Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.
Shiu W; Mok SD; Leung N; Li M; Zacharia A; Li A; Martin C
Jpn J Clin Oncol; 1987 Jun; 17(2):113-5. PubMed ID: 3039199
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group.
Yoshino M; Okazaki N; Yoshida T; Kanda Y; Miki M; Oda H; Sasagawa Y; Hayashi S; Hashimoto N
Jpn J Clin Oncol; 1989 Jun; 19(2):120-2. PubMed ID: 2471845
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of high-dose 4'epidoxorubicin in hepatocellular carcinoma.
Shiu W; Leung N; Li M; Leung WT; Li AK
Jpn J Clin Oncol; 1988 Sep; 18(3):235-7. PubMed ID: 2842522
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
[TBL] [Abstract][Full Text] [Related]
5. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
6. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
7. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
8. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.
Casanova M; Massimino M; Ferrari A; Spreafico F; Piva L; Coppa J; Luksch R; Cefalo G; Terenziani M; Polastri D; Bellani FF; Mazzaferro V
Pediatr Hematol Oncol; 2005; 22(3):189-98. PubMed ID: 16020101
[TBL] [Abstract][Full Text] [Related]
9. [The effect and pharmacokinetics of etoposide in patients with primary hepatocellular carcinoma].
Funakoshi S; Aiba K; Dobashi F; Inamoto Y; Hirano A; Tada N; Ogihara A; Fujii T; Kuraishi Y; Yamada T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):165-7. PubMed ID: 8380686
[No Abstract] [Full Text] [Related]
10. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
Ueno H; Okada S; Okusaka T; Ikeda M; Kuriyama H
Cancer Chemother Pharmacol; 2002 Feb; 49(2):155-60. PubMed ID: 11862430
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Lind PA; Naucler G; Holm A; Gubanski M; Svensson C
Acta Oncol; 2007; 46(2):230-3. PubMed ID: 17453374
[TBL] [Abstract][Full Text] [Related]
16. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma.
Cheng AL; Chen YC; Yeh KH; Chuang SE; Chen BR; Chen DS
Cancer; 1996 Mar; 77(5):872-7. PubMed ID: 8608477
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of epirubicin in hepatoma.
Shiu W; Mok SD; O SK; Tsao SY; Woo KS; Li A; Leung N; Martin C
Cancer Treat Rep; 1986 Aug; 70(8):1035-6. PubMed ID: 3015405
[No Abstract] [Full Text] [Related]
18. High dose vitamin K3 infusion in advanced hepatocellular carcinoma.
Sarin SK; Kumar M; Garg S; Hissar S; Pandey C; Sharma BC
J Gastroenterol Hepatol; 2006 Sep; 21(9):1478-82. PubMed ID: 16911696
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
20. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
